Monitor upcoming clinical trial updates from Yale and Johns Hopkins for CMND-100 — actual data readouts will be more material than policy commentary. Policy support may boost sentiment but does not reduce development risk for this micro-cap biotech.
Price Chart
Executive Summary
Clearmind Medicine (CMND) issued a press release commending a presidential executive order that prioritizes FDA review of psychedelic therapies, including its non-hallucinogenic neuroplastogen MEAI (CMND-100), for serious mental illness. The company highlighted its alignment with policy momentum and ongoing Phase I/IIa trials for alcohol use disorder, though no new clinical or financial data was provided.
Key Facts
- Clearmind Medicine praised President Trump’s April 18, 2026, Executive Order to accelerate FDA review of psychedelic breakthrough therapies.
- The company’s compound MEAI was previously named in H.R. 7091, proposed legislation to expand veteran access to emerging treatments for alcohol use disorder.
- CMND-100 is in FDA-approved Phase I/IIa trials at Yale and Johns Hopkins for alcohol use disorder.
- No new clinical results, financial figures, or guidance were disclosed in the release.
- The announcement is policy-related and forward-looking, with no immediate commercial or regulatory impact.
Financial Impact
No direct financial impact disclosed; policy tailwinds may improve long-term development prospects.
Risk Factors
- High clinical development risk typical of early-stage biotech with no approved products.
- Forward-looking statements dominate the release; no near-term catalysts confirmed.
- Micro-cap status ($1M market cap) implies extreme volatility and liquidity risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3277442 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.75%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.41%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.27%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers